CD4 and lung carcinoma: validated in both animal models and phase I clinical trials across multiple cancer types (including ovarian and lung cancers) that LDRT can remodel the immune-desert tumor microenvironment by enhancing T lymphocyte infiltration through both naive CD4+ T cells and adaptive CD4+ T cells in the immune microenvironment, achieving NKG2D-dependent tumor control (13).